BAXTER INTERNATIONAL INC. Funds and ETFs Baxter International Inc.
Equities
BAX
US0718131099
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.24 USD | -0.54% |
|
-2.44% | -8.85% |
| 13/05 | Baxter International's Clinolipid Injection Approved for Expanded Use in US | MT |
| 10/05 | TD Cowen Downgrades Baxter International to Hold From Buy, Price Target is $40 | MT |
ETFs positioned on Baxter International Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.10% | 2,517 M€ | +12.14% | - | |
| 0.09% | 50 M€ | +9.54% | ||
| 0.08% | 276 M€ | +11.40% | - | |
| 0.08% | 6 M€ | +17.98% | - | |
| 0.08% | 121 M€ | +7.29% | - | |
| 0.08% | 1 M€ | +0.04% | ||
| 0.08% | 57 M€ | +21.00% | - | |
| 0.08% | 559 M€ | +14.30% | ||
| 0.08% | 1,848 M€ | +18.39% | - | |
| 0.07% | 1,487 M€ | +7.21% | - | |
| 0.07% | 1 M€ | -.--% | ||
| 0.07% | 283 M€ | +19.85% | ||
| 0.06% | 234 M€ | +3.34% | - | |
| 0.06% | 655 M€ | -.--% | - | |
| 0.06% | 1,174 M€ | +23.54% | ||
| 0.06% | 273 M€ | -.--% | ||
| 0.05% | 34 M€ | +11.62% | - | |
| 0.05% | 0 M€ | 0.00% | - | |
| 0.05% | 571 M€ | +7.35% | - | |
| 0.05% | 14 M€ | +16.19% | - | |
| 0.04% | 23 M€ | -.--% | - | |
| 0.04% | 786 M€ | -.--% | ||
| 0.04% | 7 M€ | +6.18% | - | |
| 0.04% | 32 M€ | +1.80% | - | |
| 0.04% | 17 M€ | +6.18% | - | |
| 0.04% | 414 M€ | +11.73% | - | |
| 0.04% | 1,006 M€ | -.--% | - | |
| 0.04% | 169 M€ | -0.42% | - | |
| 0.04% | 34 M€ | +8.28% | - | |
| 0.04% | 206 M€ | -.--% | ||
| 0.04% | 375 M€ | +8.28% | ||
| 0.04% | 284 M€ | -.--% |
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows:
- medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.);
- kidney dialysis drugs and equipment (30.1%);
- systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.;
- other (20.1%).
Export accounts for 52.7% of net sales.
Calendar
16/05/2024
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
35.24
USD
Average target price
46.47
USD
Spread / Average Target
+31.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.85% | 17.96B | |
| -5.51% | 181B | |
| +2.33% | 112B | |
| -3.62% | 67.92B | |
| +1.52% | 50.1B | |
| +8.06% | 44.27B | |
| +9.39% | 40.41B | |
| +23.35% | 31.95B | |
| +0.67% | 25.82B | |
| +17.27% | 25.29B |
- Stock Market
- Equities
- BAX Stock
- Funds and ETFs Baxter International Inc.